Phibro Animal Health Corporation Earnings Recaps
Q2 2026
Feb 5, 2026
Phibro Animal Health Corporation reported strong second-quarter results, with a 26% increase in animal health sales and a substantial 41% rise in adjusted EBITDA, reflecting effective integration strategies and robust demand across key sectors.
Key takeaways
- Animal health sales surged by 26%, led by a 34% growth in medicated feed additives.
- Consolidated sales rose 21% to $373.9 million, with EBITDA reflecting a 41% increase.
- Full-year sales and earnings guidance has been raised based on strong momentum and operational performance.
- Positive feedback from customers and strong leadership alignment highlight the company’s strategic execution and market position.
- Leadership transition slated for July is expected to reinforce momentum and operational excellence.
Q4 2025
Aug 28, 2025
Strong demand in the Animal Health segment propelled Phibro Animal Health Corporation to a robust finish in fiscal 2025, with significant sales growth and operational leverage improvements.
Key takeaways
- Q4 consolidated net sales rose 39% to $378.7 million, driven by a 53% increase in the Animal Health segment.
- Adjusted EBITDA for Q4 increased by 49%, highlighting effective cost management and operational efficiencies.
- The fiscal year concluded with total revenues of $1.296 billion, a 27% increase year-over-year, and adjusted EBITDA growth of 65%.
- Guidance for fiscal 2026 projects net sales between $1.425 billion and $1.475 billion, reflecting confidence in ongoing momentum.
- Continued success attributed to the integration of the MFA business and advancements from the Phibro Forward strategy.